Symbols

PLX

Protalix·AMEX

--(--)

PLX Profile

Protalix Biotherapeutics, Inc.

A biopharmaceutical company that uses plant cell technology to produce recombinant proteins

Industry

Biological Technology

Established Date

Listing Date

03/12/2007

Exchange

American Stock Exchange

Full-time Employees

226

Fiscal Year Ends

12-31

Website

www.protalix.com

Security Type

Common stock

Office address

2 University Plaza , Suite 100 , Hackensack , NJ 07601

Business

Focus on the development and commercialization of recombinant therapeutic proteins with the company's proprietary ProCellEx protein expression system.

Introduction

Protalix Biotherapeutics, Inc., was originally incorporated in Florida in April 1992 and re-incorporated in Delaware in March 2016. The Company is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for rare diseases using its proprietary plant cell protein expression system, ProCellEx. It has two approved products, Elelyso for Gaucher disease and Elfabrio for Fabry disease, commercialized through partnerships with Pfizer and Casey, respectively.